Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children Undergoing Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 1, 2008, Pages 88-98

  Bartelink, Imke H ^a   Bredius, Robbert G M ^b   Ververs, Tessa T ^a   Raphael, Martine F ^a   van Kesteren, Charlotte ^a   Bierings, Marc ^a   Rademaker, Carin M A ^a   den Hartigh, J ^b   Uiterwaal, Cuno S P M ^a   Zwaveling, Juliette ^b   Boelens, Jaap J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allogeneic stem cell transplantation; Busulfan; Therapeutic drug monitoring

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIEMETIC AGENT; BUSULFAN; CIPROFLOXACIN; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFIBROTIDE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; MELPHALAN; METHOTREXATE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG MONITORING; ENGRAFTMENT; FANCONI ANEMIA; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HIGH RISK PATIENT; HUMAN; INBORN ERROR OF METABOLISM; INFANT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; SURVIVAL RATE; TREATMENT OUTCOME; VEIN OCCLUSION;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; BUSULFAN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 37349060017     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.09.015     Document Type: Article

References (50)

1. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 25 (2000) 925-930
2. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16 (1995) 31-42
3. Tran H.T., Madden T., Petropoulos D., et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 26 (2000) 463-470
4. Michel G., Gluckman E., Esperou-Bourdeau H., et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation-a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 12 (1994) 1217-1222
5. Bleyzac N., Souillet G., Magron P., et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 28 (2001) 743-751
6. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6 (2000) 548-554
7. Cremers S., Schoemaker R., Bredius R., et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 53 (2002) 386-389
8. Nguyen L., Fuller D., Lennon S., Leger F., and Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 33 (2004) 979-987
9. Tran H.T., Petropoulos D., Worth L.L., ullen C.A., adden T., ndersson B.S., horoszy M., guyen J., ebb S.K., and han K.W. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 10 11 (2004) 805-812 Ref Type: Generic
10. Vassal G., Michel G., Esperou H., et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 61 (2008) 113-123
11. Zwaveling J., Bredius R.G., Cremers S.C., et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 35 (2005) 17-23
12. Zwaveling J., den Hartigh J., Lankester A.C., et al. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Anticancer Drugs 17 (2006) 1099-1105
13. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17 (1996) 225-230
14. Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25 (1989) 55-61
15. Ljungman P., Hassan M., Bekassy A.N., Ringden O., and Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 20 (1997) 909-913
16. McCune J.S., Gibbs J.P., and Slattery J.T. Plasma concentration monitoring of busulfan: does it improve clinical outcome?. Clin Pharmacokinet 39 (2000) 155-165
17. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997) 3055-3060
18. Small T.N., Young J.W., Castro-Malaspina H., et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol. Blood Marrow Transplant 13 (2007) 235-244
19. Ouachee-Chardin M., Elie C., de Saint B.G., et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics 117 (2006) e743-e750
20. Horne A., Janka G., Maarten E.R., et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol 129 (2005) 622-630
21. Henter J.I., Samuelsson-Horne A., Arico M., et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100 (2002) 2367-2373
22. Boelens J.J., Wynn R.F., O'meara A., et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant (2007)
23. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 28 (2001) 1013-1018
24. Bouligand J., Boland I., Valteau-Couanet D., et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 32 (2003) 979-986
25. Aggarwal C., Gupta S., Vaughan W.P., et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 12 (2006) 770-777
26. Pawlowska A.B., Blazar B.R., Angelucci E., et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 20 (1997) 915-920
27. Fernandez H.F., Tran H.T., Albrecht F., et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 8 (2002) 486-492
28. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8 (2002) 468-476
29. Ryu S.G., Lee J.H., Choi S.J., et al. Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 13 (2007) 1095-1105
30. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8 (2002) 145-154
31. Shaw P.J., Nath C., Berry A., and Earl J.W. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages. Bone Marrow Transplant 34 (2004) 197-205
32. Bartelink I.H., Rademaker C.M., Schobben A.F., and van den Anker J.N. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin.Pharmacokinet 45 (2006) 1077-1097
33. Pineiro-Carrero V.M., and Pineiro E.O. Liver. Pediatrics 113 (2004) 1097-1106
34. Strolin B.M., and Baltes E.L. Drug metabolism and disposition in children. Fundam Clin Pharmacol 17 (2003) 281-299
35. Kearns G.L. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J.Allergy Clin.Immunol 106 (2000) S128-S138
36. de Wildt S.N., Kearns G.L., Leeder J.S., and van den Anker J.N. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin.Pharmacokinet 36 (1999) 439-452
37. de Wildt S.N., Kearns G.L., Leeder J.S., and van den Anker J.N. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37 (1999) 485-505
38. Proost J.H., and Meijer D.K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22 (1992) 155-163
39. Bearman S.I. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 85 (1995) 3005-3020
40. S.Corbacioglu and M.Lacobelli. VOD-DF study, prospective study of the incidence and outcome of venoocclusive disease (VOD) with the prophylactic use of defibrotide in pediatric stem cell transplantation. Version 4.0. 2-11-2004.
41. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
42. Kurth T., Walker A.M., Glynn R.J., et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163 (2006) 262-270
43. Hassan M., Ljungman P., Bolme P., et al. Busulfan bioavailability. Blood 84 (1994) 2144-2150
44. Ryu S.G., Lee J.H., Choi S.J., et al. Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation. Biol. Blood Marrow Transplant 13 (2007) 1095-1105
45. Boelens J.J., Wynn R.F., O'Meara A., et al. Outcomes of Haematopoietic Stem Cell Transplantation for Hurler's Syndrome in Europe: a Risk Factor Analysis for Graft-Failure. Bone marrow transplantation (2007) In Press
46. Jones R.J., Lee K.S., and Beschorner W.E. Venocclusive disease of the liver following bone marrow transplantation. Transplantation 44 (1975) 778-783
47. Ryu S.G., Lee J.H., Choi S.J., et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 13 (2007) 1095-1105
48. Tiedemann K., Waters K.D., Tauro G.P., Tucker D., and Ekert H. Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 82 (1993) 3730-3738
49. McDonald G.B., Sharma P., Matthews D.E., Shulman H.M., and Thomas E.D. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4 (1984) 116-122
50. Hempel G., Oechtering D., Lanvers-Kaminsky C., et al. Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan. J Clin Oncol 25 (2007) 1772-1778